Cheaper eye drug proves as good as pricier one

Apr 28, 2011 By MARILYNN MARCHIONE , AP Medical Writer

A new study shows that a cheaper drug for a common eye disease is as effective as a more expensive one approved for the condition.

The study found that vision improvement was the same among patients given monthly shots of Avastin (ah-VAS-tin) or Lucentis (loo-SEN-tis) for one year. The patients have an disease called wet macular degeneration - a common cause of blindness in the elderly.

Avastin is a cancer that many doctors have used to treat the eye disorder even though it wasn't approved for that use. It costs about $50 per treatment compared to $2,000 for Lucentis. Both drugs are sold by Roche's Genentech unit.

Results were published online Thursday by the and will be presented at a meeting on Sunday.

Explore further: India's meth addiction grows as criminals tap chemical hub

not rated yet
add to favorites email to friend print save as pdf

Related Stories

Can further studies lower the cost of preserving vision?

Oct 04, 2006

The results of two large, randomized clinical trials published October 5, 2006, in the New England Journal of Medicine demonstrate that the drug ranibizumab is an effective treatment for neovascular macular degeneration, a comp ...

FDA says breast cancer drug did not extend lives

Jul 16, 2010

(AP) -- Federal health scientists said Friday that follow-up studies of a Roche breast cancer drug show it failed to slow tumor growth or extend patient lives, opening the door for a potential withdrawal in that indication.

Recommended for you

Determine patient preferences by means of conjoint analysis

Jul 29, 2014

The Conjoint Analysis (CA) method is in principle suitable to find out which preferences patients have regarding treatment goals. However, to widely use it in health economic evaluations, some (primarily methodological) issues ...

FDA approves hard-to-abuse narcotic painkiller

Jul 25, 2014

(HealthDay)—A new formulation of a powerful narcotic painkiller that discourages potential abusers from snorting or injecting the drug has been approved by the U.S. Food and Drug Administration.

Race affects opioid selection for cancer pain

Jul 25, 2014

(HealthDay)—Racial disparities exist in the type of opioid prescribed for cancer pain, according to a study published online July 21 in the Journal of Clinical Oncology.

FDA approves tough-to-abuse formulation of oxycodone

Jul 25, 2014

(HealthDay)—Targiniq ER (oxycodone hydrochloride and naloxone hydrochloride extended release) has been approved by the U.S. Food and Drug Administration as a long-term, around-the-clock treatment for severe ...

User comments : 0